

TRANSPLANT REFERRAL FORM (Page 1 of 2)

DEDICATED PROVIDER LINE 855.896.9252 | MAIN LINE 888.370.1724 | FAX 877.645.7514



Remove above portion before faxing. Please complete the prescription form in its entirety and fax with secure cover sheet to the number above.

PATIENT INFORMATION

| | | | | | |
|--|------------|------------|--|-------------------|------------------|
| Last Name | First Name | DOB | Gender <input type="checkbox"/> M <input type="checkbox"/> F | Last 4 SSN | Primary Language |
| Address | | | City | State | ZIP |
| Email | Home Phone | Work Phone | Cell Phone | | |
| Primary Contact Method (check one) <input type="checkbox"/> Cell Phone <input type="checkbox"/> Home Phone <input type="checkbox"/> Work Phone <input type="checkbox"/> Text <input type="checkbox"/> Email <input type="checkbox"/> Primary Caregiver <input type="checkbox"/> DO NOT CONTACT | | | | | |
| Primary Caregiver/Alt Contact Name (If applicable) | | | Alt Contact Email | Alt Contact Phone | |

PRESCRIBER INFORMATION

| | | | | | |
|----------------------------------|-----------------------------|---|-----------------|-----|--|
| Name of Contact Sending Referral | Title | Preferred Contact Method (check one) <input type="checkbox"/> Email <input type="checkbox"/> Phone <input type="checkbox"/> Fax | | | |
| Referral Contact Email | Office Phone | Office Fax | | | |
| Practice / Facility Name | Prescriber Name / Specialty | | | | |
| Address | | City | State | ZIP | |
| Prescriber State License # | DEA # | NPI # | Medicaid UPIN # | | |

** Please include a copy of the front and back of insurance card **

CLINICAL INFORMATION - Please include applicable clinical chart notes

| | | | |
|--|--------------------|--|------------------------|
| Prescription Type <input type="checkbox"/> Naïve/New Start <input type="checkbox"/> Therapy Restart <input type="checkbox"/> Existing Treatment | | | |
| Therapy Start Date | Date of Transplant | Date of Discharge | Date Medication Needed |
| Other/Concomitant Medications (please list) | | | |
| Allergies <input type="checkbox"/> NKDA <input type="checkbox"/> Drug Allergies (please list) | | <input type="checkbox"/> Other (please list) | |
| Ship to Address <input type="checkbox"/> Home <input type="checkbox"/> Prescriber's Office <input type="checkbox"/> Other (please list) | | | |
| Patient Height (cm/in) | | Patient Weight (kg/lbs) | Date Obtained |
| ICD-10 Codes <input type="checkbox"/> Kidney (Z94.0) <input type="checkbox"/> Kidney/Pancreas (Z94.0/Z94.83) <input type="checkbox"/> Heart (Z94.1) Lung (Z94.2) <input type="checkbox"/> Heart/Lung (Z94.3) <input type="checkbox"/> Liver (Z94.4) <input type="checkbox"/> Bone Marrow (Z94.81) <input type="checkbox"/> Intestines (Z94.82) <input type="checkbox"/> Pancreas (Z94.83) <input type="checkbox"/> B25 CMV disease <input type="checkbox"/> B25.9 CMV disease, unspecified <input type="checkbox"/> Other Code _____ Description _____ | | | |

PRESCRIPTION INFORMATION - Please Escribe if required by state law

In order for a brand name product to be dispensed, the prescriber must handwrite "Brand Necessary" or "Brand Medically Necessary," or your state-specific required language to prohibit substitutions. This form is not a valid prescription form for writing controlled medications.

| MEDICATION | DOSE | DIRECTIONS | QTY | REFILLS |
|------------|------|------------|-----|---------|
|------------|------|------------|-----|---------|

IMMUNOSUPPRESSANTS

| | | | | |
|--|---|--|--|--|
| <input type="checkbox"/> Azathioprine | <input type="checkbox"/> 50 mg tablet <input type="checkbox"/> 50 mg/mL compd susp | | | |
| <input type="checkbox"/> Cyclosporine modified | <input type="checkbox"/> 25 mg <input type="checkbox"/> 100 mg capsule <input type="checkbox"/> 100 mg/mL solution (unbreakable bottle of 50 mL) | | | |
| <input type="checkbox"/> Everolimus | <input type="checkbox"/> 0.25 mg tablet <input type="checkbox"/> 1 mg tablet <input type="checkbox"/> 0.5 mg tablet <input type="checkbox"/> 2.5 mg tablet <input type="checkbox"/> 0.75 mg tablet <input type="checkbox"/> 5 mg tablet | | | |
| <input type="checkbox"/> Mycophenolate | <input type="checkbox"/> 250 mg capsule <input type="checkbox"/> 500 mg tablet <input type="checkbox"/> 200 mg/mL suspension (unbreakable bottle of 160ml) | | | |
| <input type="checkbox"/> Mycophenolic acid | <input type="checkbox"/> 180 mg tablet <input type="checkbox"/> 360 mg tablet | | | |
| <input type="checkbox"/> Nulojix (belatacept) | <input type="checkbox"/> 250 mg vial | | | |
| <input type="checkbox"/> Prednisone | <input type="checkbox"/> 1 mg tablet <input type="checkbox"/> 10 mg tablet <input type="checkbox"/> 2.5 mg tablet <input type="checkbox"/> 20 mg tablet <input type="checkbox"/> 5 mg tablet <input type="checkbox"/> 5mg/mL solution | | | |
| <input type="checkbox"/> Prednisolone | <input type="checkbox"/> 5 mg/mL solution <input type="checkbox"/> 5 mg/5 mL solution <input type="checkbox"/> 15 mg/5 mL solution | | | |
| <input type="checkbox"/> Prograf granules | <input type="checkbox"/> 0.2 mg <input type="checkbox"/> 1 mg | | | |
| <input type="checkbox"/> Sirolimus | <input type="checkbox"/> 0.5 mg tablet <input type="checkbox"/> 1 mg/mL solution (unbreakable bottle of 60 mL) <input type="checkbox"/> 1 mg tablet <input type="checkbox"/> 2 mg tablet | | | |

Total RXs _____

Prescriber Signature _____

Date _____

Supervising Physician Signature (where required by state law) _____

Date _____

DAW (Dispense as Written) _____

Date _____

Brand Necessary (must handwrite) _____

Note: The information contained in this document will become a legal prescription. Prescriber is to comply with his/her state specific Pharmacy and Medical Board guidelines such as e-prescribing, state specific prescription form, fax language, number of prescriptions allowed on a single prescription form, etc. If more than one page is required, make additional copies. Non-compliance with state specific requirements could result in outreach to the prescriber.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain proprietary and confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.

Remove above portion before faxing. Please complete the prescription form in its entirety and fax with secure cover sheet to the number above.

MAIN INFORMATION (MUST BE FILLED OUT TO PROCESS PAGES TOGETHER)

| | | | | | | |
|--------------------|--|--------------------|-------|-------|---------------|--|
| Patient Last Name | | Patient First Name | | DOB | Date of Issue | |
| Patient Address | | | City | State | ZIP | |
| Prescriber Name | | | NPI # | DEA # | | |
| Prescriber Address | | | City | State | ZIP | |

PRESCRIPTION INFORMATION - Please Escribe if required by state law
 In order for a brand name product to be dispensed, the prescriber must handwrite "Brand Necessary" or "Brand Medically Necessary," or your state-specific required language to prohibit substitutions. This form is not a valid prescription form for writing controlled medications.

| MEDICATION | DOSE | DIRECTIONS | QTY | REFILLS |
|------------|------|------------|-----|---------|
|------------|------|------------|-----|---------|

| | | | | |
|--|---|--------------------------------------|--|--|
| IMMUNOSUPPRESSANTS CONTINUED | | | | |
| <input type="checkbox"/> Envarsus XR (Tacrolimus ER) | <input type="checkbox"/> 0.75 mg tablet <input type="checkbox"/> 1 mg tablet | <input type="checkbox"/> 4 mg tablet | | |
| <input type="checkbox"/> Tacrolimus IR | <input type="checkbox"/> 0.5 mg capsule <input type="checkbox"/> 1 mg capsule <input type="checkbox"/> 5 mg capsule <input type="checkbox"/> 0.5 mg/mL cmpd susp | | | |

| | | | | |
|---------------------------------------|--|--|--|--|
| ANTIFUNGALS | | | | |
| <input type="checkbox"/> Clotrimazole | <input type="checkbox"/> 10 mg troche | | | |
| <input type="checkbox"/> Fluconazole | <input type="checkbox"/> 100 mg tablet <input type="checkbox"/> 150 mg tablet <input type="checkbox"/> 200 mg tablet <input type="checkbox"/> 10 mg/mL suspension (unbreakable bottle of 35 mL) | | | |
| <input type="checkbox"/> Nystatin | <input type="checkbox"/> 100,000 u/mL suspension | | | |

| | | | | |
|---|--|---|--|--|
| ANTIVIRALS | | | | |
| <input type="checkbox"/> Livtency™ | <input type="checkbox"/> 200 mg Tablet | STANDARD DOSE <input type="checkbox"/> Take two tablets (400 mg) by mouth twice daily, with or without food ADJUSTED DOSING (PER LIVTENCITY PRESCRIBING INFORMATION, ADJUSTED DOSING IS RECOMMENDED FOR THE FOLLOWING CONCOMITANT MEDICATIONS): Carbamazepine <input type="checkbox"/> Take four tablets (800 mg) by mouth twice daily, with or without food Phenobarbital <input type="checkbox"/> Take six tablets (1,200 mg) by mouth twice daily, with or without food Phenytoin <input type="checkbox"/> Take six tablets (1,200 mg) by mouth twice daily, with or without food | | |
| <input type="checkbox"/> Valganciclovir | <input type="checkbox"/> 450 mg tablet <input type="checkbox"/> 50 mg/mL solution (unbreakable bottle of 88 mL) | | | |

| | | | | |
|---|--|--|--|--|
| PCP PROPHYLAXIS/ANTIBIOTICS | | | | |
| <input type="checkbox"/> Ciprofloxacin | <input type="checkbox"/> 250 mg tablet <input type="checkbox"/> 500 mg tablet <input type="checkbox"/> Cipro 250 mg/5 mL suspension (unbreakable bottle of 100 mL) | | | |
| <input type="checkbox"/> Dapsone | <input type="checkbox"/> 25 mg tablet <input type="checkbox"/> 100 mg tablet <input type="checkbox"/> 2 mg/mL cmpd suspension | | | |
| <input type="checkbox"/> SMZ/trimethoprim | <input type="checkbox"/> 400 mg/80 mg SS <input type="checkbox"/> 800 mg/160 mg DS <input type="checkbox"/> 200 mg/40 mg/5 mL susp | | | |

| | | | | |
|--------------------------------|--|--|--|--|
| MISCELLANEOUS | | | | |
| <input type="checkbox"/> Other | | | | |
| <input type="checkbox"/> Other | | | | |

| | |
|---------------------------------------|--|
| WELCOME KIT | |
| <input type="checkbox"/> Standard Kit | Includes: Lip balm, Sunscreen, Lotion, Tote Bag, Thermometer, Pill Box |
| <input type="checkbox"/> Add Ons | Select up to 2: <input type="checkbox"/> Scale <input type="checkbox"/> Blood Pressure Monitor <input type="checkbox"/> Blood Glucose Monitoring Kit |

Total RXs _____

| | | | |
|---------------------------|------|---|------|
| Prescriber Signature | Date | Supervising Physician Signature (where required by state law) | Date |
| DAW (Dispense as Written) | Date | Brand Necessary (must handwrite) | |

Note: The information contained in this document will become a legal prescription. Prescriber is to comply with his/her state specific Pharmacy and Medical Board guidelines such as e-prescribing, state specific prescription form, fax language, number of prescriptions allowed on a single prescription form, etc. If more than one page is required, make additional copies. Non-compliance with state specific requirements could result in outreach to the prescriber.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.